Amanda Bruno, Senior Director, Value Evidence Leader, GSK
Dr. Bruno has 17 years’ experience in healthcare and currently leads the global Value Evidence & Outcomes (VEO) team for GSK Oncology, supporting assets in early development and in clinic. Prior to this, she led the US Specialty health economics and outcomes research (HEOR) team at Bristol-Myers Squibb. Before joining industry, Dr. Bruno was a Senior Director in Scientiﬁc Consulting at Xcenda—a consultancy owned by Amerisource Bergen Corporation. In this role, she specialized in global health economics, real-world evidence, outcomes research, and market intelligence to demonstrate product value and drive market access for several large, mid-size and small pharmaceutical and biotech companies. Before joining Xcenda, Dr. Bruno was also responsible for leading a health services research team that supported industry and managed care for a consultancy that is now part of IMS Health. Dr. Bruno began her career as a Research Fellow for the Centers for Disease Control and Prevention, where she worked with the Prevention Effectiveness Branch publishing economic evidence-based recommendations for effective community based programs supported by the US Preventive Services Task Force.
Dr. Bruno’s experience ranges across several disease areas and she has authored a variety of scientiﬁc publications appearing in Health Services Research, Medical Care, Radiology, AIDS Care, Journal of Oncology Practice, American Health & Drug Beneﬁts, and the Journal of Urology, among others. Dr. Bruno received her PhD in Health Services with a cognate in Pharmacoeconomics from UCLA where she was a recipient of the UCLA/RAND Health Services Research Training Grant supported by the Agency for Health Care Research Quality. Her MPH in Health Policy and Management was completed at Emory University and her Bachelor of Science at Tulane University.